Drugs / Ginaton
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT07236645 | Nov 2025 → Dec 2028 expected | diabetic retinopathy | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Not yet recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02026479 | Jan 2014 → Dec 2016 | sudden hearing loss disorder | Peking University People's Hospital | Unknown | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 4 | NCT04192656 Background | Nov 2019 → Dec 2024 overdue | obstructive sleep apnea syndrome, sudden sensorineural hearing loss | Beijing Tsinghua Chang Gung Hospital | Recruiting | No outcome recorded |
| — | NCT05169450 Comparator | Jul 2013 → Apr 2014 | brain ischemia, cerebral infarction | Dongzhimen Hospital, Beijing | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ginaton | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02026479 ↗ |
| Known as | ginkgo biloba extract tablet | “Ginaton (ginkgo biloba extract tablet)” NCT07236645 ↗ |
| Route | Oral | “40mg/pill, 3times/day,oral” NCT02026479 ↗ |